Author:
Höchsmann Christoph,Dorling James L,Lavie Carl J,Katzmarzyk Peter T
Funder
Patient-Centered Outcomes Research Institute
National Institute of General Medical Sciences
National Institute of Diabetes and Digestive and Kidney Diseases
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Lavie CJ, Bhatt DL, Neeland IJ, Heymsfield SB. Editorial commentary: weight loss for cardiovascular disease prevention - is semaglutide the answer? Trends Cardiovasc Med. 2023;33:167–9.
2. Arena R, Pronk NP, Lavie CJ. Pharma-cise in the glucagon-like peptide-1 receptor agonists era. A concept whose time has come. Mayo Clinic Proceedings. 2024;in press.
3. Katzmarzyk PT, Martin CK, Newton RL, Apolzan JW, Arnold CL, Davis TC, et al. Weight loss in Underserved patients — a cluster-randomized trial. N Engl J Med. 2020;383:909–18.
4. Höchsmann C, Dorling JL, Martin CK, Newton RL, Apolzan JW, Myers CA, et al. Effects of a 2-Year primary care lifestyle intervention on cardiometabolic risk factors: a cluster-randomized trial. Circulation. 2021;143:1202–14.
5. Kaplan LM, Golden A, Jinnett K, Kolotkin RL, Kyle TK, Look M, et al. Perceptions of barriers to effective obesity care: results from the National ACTION Study. Obes (Silver Spring). 2018;26:61–9.